ReviewKeynoteRNAi-combined nano-chemotherapeutics to tackle resistant tumors

- Nanotechnology can protect siRNA against RNAse degradation.
- siRNA adopts an alternative pathway to knock genes with high specificity to cure cancer.
- An ideal vector is anticipated to preserve siRNA from degradation, while delivering it to desired site.
- More research is still warranted to develop an ideal vector for the simultaneous delivery of siRNA and drug.

The merger of nanotechnology and combination chemotherapy has shown notable promise in the therapy of resistant tumors. The latest scientific attention encompasses the engagement of anticancer drugs in combination with small interfering (si)RNAs, such as VEGF, XLAP, PGP, MRP-1, BCL-2 and cMyc, to name but a few. siRNAs have shown immense promise to knockout drug resistance genes as well as to recover the sensitivity of resistant tumors to anticancer therapy. The nanotechnology approach could also protect siRNA against RNAse degradation as well as prevent off-target effects. In this article, we discuss the approaches that have been used to deliver of siRNA in combination with chemotherapeutic drugs to treat resistant tumors. We also discuss the stipulations that must be considered in formulating a nanotechnology-assisted siRNA-drug cancer therapy.